製薬業界にふさわしい礼儀

Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma.

British journal of cancer·2013

Continuing professional development systems and requirements for graduate dentists in the EU: survey results from the DentCPD project.

European journal of dental education : official journal of the Association for Dental Education in Europe·2013

Core continuing professional development (CPD) topics for the European dentist.

European journal of dental education : official journal of the Association for Dental Education in Europe·2013

Core continuing professional development (CPD) topics for the European dentist.

European journal of dental education : official journal of the Association for Dental Education in Europe·2013

Continuing professional development systems and requirements for graduate dentists in the EU: survey results from the DentCPD project.

European journal of dental education : official journal of the Association for Dental Education in Europe·2013

Synthetic lethality to overcome cancer drug resistance.

Current medicinal chemistry·2012

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

[THE PHARMACEUTICAL HUMANITIES IN RUSSIA AND FOR RUSSIA].

Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny·2026

Research Needs in Philippine Pharmaceutical Sciences: A Qualitative Perspective from Regulatory and Clinical Research Sectors of the Pharmaceutical Industry.

Acta medica Philippina·2026

[The Role of Pharmaceutical Universities in Strengthening Japan's Drug Discovery Capabilities: A Pharmaceutical Industry Perspective].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·2026

A randomized, open-label, three-period, cross-over, single intravenous or intramuscular dose, pharmacokinetics and bioequivalence study of vitamin K<sub>1</sub> in healthy adults.

Naunyn-Schmiedeberg's archives of pharmacology·2026

Academic Influence and Industry Funding in Platelet-Rich Plasma Injections: Coauthorship Network Analysis.

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews·2026

Rupturing the Temporality of Pharmaceutical Patents: A Sketch for a New Temporal Economy of Pharmaceutical Markets.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics·2025

関連する実験動画

製薬業界にふさわしい礼儀

関連する概念動画

Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma.

Continuing professional development systems and requirements for graduate dentists in the EU: survey results from the DentCPD project.

Core continuing professional development (CPD) topics for the European dentist.

Core continuing professional development (CPD) topics for the European dentist.

Continuing professional development systems and requirements for graduate dentists in the EU: survey results from the DentCPD project.

Synthetic lethality to overcome cancer drug resistance.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

[THE PHARMACEUTICAL HUMANITIES IN RUSSIA AND FOR RUSSIA].

Research Needs in Philippine Pharmaceutical Sciences: A Qualitative Perspective from Regulatory and Clinical Research Sectors of the Pharmaceutical Industry.

[The Role of Pharmaceutical Universities in Strengthening Japan's Drug Discovery Capabilities: A Pharmaceutical Industry Perspective].

A randomized, open-label, three-period, cross-over, single intravenous or intramuscular dose, pharmacokinetics and bioequivalence study of vitamin K<sub>1</sub> in healthy adults.

Academic Influence and Industry Funding in Platelet-Rich Plasma Injections: Coauthorship Network Analysis.

Rupturing the Temporality of Pharmaceutical Patents: A Sketch for a New Temporal Economy of Pharmaceutical Markets.

関連する実験動画

製薬業界にふさわしい礼儀

関連する概念動画

関連記事